Gapping up
In reaction to strong earnings/guidance: KTCC +18.6%, HA +7.7%, ETH +6.9%, STM +5.4%, BIIB +5.2%, CA +4.8%, MRCY +4.2%, NRZ +2.3%,SMED +2.1%, COF +1.4%, SYK +1.2%, (CFO William R. Jellison will retire to pursue other interests; Glenn S. Boehnlein to assume CFO role effective April 1 ), TXT +1.1%, CNI +0.9%, ITW +0.8%, ZHNE +0.7%, NSC +0.5%
M&A news: TEX +2.7% (cont momentum on M&A spec, despite chairman downplaying rumors)
Other news: APPY +44% (Venaxis announces series of agreements for a transaction with Strand Life Sciences ), CAPN +31.8% ( entered into an exclusive distribution agreement with Bemes ), FATE +16.1% (FDA has cleared the Co's investigational new drug application for ProTmune; Co plans to initiate Phase1/2 clinical trial in mid-2016), SUNE +3.6% (SunEdison and Greenlight Capital announce two mutually agreed upon corporate governance initiatives), RMAX +2.7% (to join S&P SmallCap 600), EGL +2.1% ( awarded an $82 mln sole source renewal contract from the U.S. Department of Defense ), FDX +2.1% (authorizes new share repurchase program of up to 25 mln shares), KOS +1.8% (Guembeul-1 exploration well has made a significant gas discovery; provides operational/financial update), LM +0.8% (CEO/Chairman/Presidentdisclosed purchase of 25K shares, worth total of $745.3K and CFO disclosed purchase of 20K shares, worth total of $598.4K), GILD +0.8% (in symp with BIIB earnings)
Analyst comments: RPTP +12.1% (upgraded to Buy from Neutral at Citigroup), FIT +2.3% (initiated with a Buy at Citigroup), AAL +1.5% (upgraded to Buy from Neutral at UBS), SYK +1.2% (upgraded to Buy from Hold at Brean Capital)
In reaction to strong earnings/guidance: KTCC +18.6%, HA +7.7%, ETH +6.9%, STM +5.4%, BIIB +5.2%, CA +4.8%, MRCY +4.2%, NRZ +2.3%,SMED +2.1%, COF +1.4%, SYK +1.2%, (CFO William R. Jellison will retire to pursue other interests; Glenn S. Boehnlein to assume CFO role effective April 1 ), TXT +1.1%, CNI +0.9%, ITW +0.8%, ZHNE +0.7%, NSC +0.5%
M&A news: TEX +2.7% (cont momentum on M&A spec, despite chairman downplaying rumors)
Other news: APPY +44% (Venaxis announces series of agreements for a transaction with Strand Life Sciences ), CAPN +31.8% ( entered into an exclusive distribution agreement with Bemes ), FATE +16.1% (FDA has cleared the Co's investigational new drug application for ProTmune; Co plans to initiate Phase1/2 clinical trial in mid-2016), SUNE +3.6% (SunEdison and Greenlight Capital announce two mutually agreed upon corporate governance initiatives), RMAX +2.7% (to join S&P SmallCap 600), EGL +2.1% ( awarded an $82 mln sole source renewal contract from the U.S. Department of Defense ), FDX +2.1% (authorizes new share repurchase program of up to 25 mln shares), KOS +1.8% (Guembeul-1 exploration well has made a significant gas discovery; provides operational/financial update), LM +0.8% (CEO/Chairman/Presidentdisclosed purchase of 25K shares, worth total of $745.3K and CFO disclosed purchase of 20K shares, worth total of $598.4K), GILD +0.8% (in symp with BIIB earnings)
Analyst comments: RPTP +12.1% (upgraded to Buy from Neutral at Citigroup), FIT +2.3% (initiated with a Buy at Citigroup), AAL +1.5% (upgraded to Buy from Neutral at UBS), SYK +1.2% (upgraded to Buy from Hold at Brean Capital)